Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
Abbott has previously opposed legislation to test strips, but noted an 89% increase in fentanyl deaths in Texas over the past year.
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.
The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
Hidradenitis Suppurativa in 2025: Year in Review
1.
Atezolizumab Consolidation Impresses in High-Risk DLBCL
2.
Breast cancer: Why it's difficult to treat and what new approaches are on the horizon
3.
Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.
4.
Error on the MGUS-Autoimmune Disease Association.
5.
Veterans of the Navy have high lung cancer rates associated with asbestos use.
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
3.
The Importance of Balanced Potassium Levels in Maintaining Good Health
4.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
5.
Optimizing the Diagnosis and Treatment of Hematological Diseases Through Artificial Intelligence
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
2.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
3.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
5.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge